Could This Seattle Pot Stock SOAR as Legal Weed Market Expands?
Fifteen states plus the District of Columbia now permit the recreational use of cannabis and Congress is on track to decriminalize marijuana possession on the federal level. As a result, the North American cannabis market is expected to TRIPLE in size from $30 billion to $100 billion by the year 2027 – and one Seattle manufacturer is poised to cash in!
Details in Brand-New Special Report!
Serge Saxonov, insider at 10x Genomics
Serge Saxonov Insider Alerts

Get notified the next time Serge Saxonov buys or sells 10x Genomics stock. Enter your email address below to get our daily insider buying and selling report.

Serge Saxonov Insider Information

CEO of 10x Genomics
Serge Saxonov co-founded 10x Genomics in 2012. As the CEO, he defined the 10x vision and strategy, contributed to core inventions, and has led the company since inception. Prior to 10x Genomics, Serge was Vice President of Applications at QuantaLife, where he built products and defined the company’s growth areas. Serge was the first employee at 23andMe, where he served as Founding Architect and Director of R&D. There he defined the initial concept of the product, built out the core technology, and drove strategy and execution of R&D functions. Serge received a Ph.D. in biomedical informatics from Stanford University and an A.B. in applied mathematics from Harvard College.

What is Serge Saxonov's net worth?

The estimated net worth of Serge Saxonov is at least $131.86 million as of June 8th, 2021. Dr. Saxonov owns 904,068 shares of 10x Genomics stock worth more than $131,858,318 as of November 29th. This net worth approximation does not reflect any other assets that Dr. Saxonov may own. Additionally, Dr. Saxonov receives a salary of $654,990.00 as CEO at 10x Genomics. Learn More.

How old is Serge Saxonov?

Dr. Saxonov is currently 44 years old. There are 4 older executives and no younger executives at 10x Genomics. Learn More.

What is Serge Saxonov's salary?

As the CEO of 10x Genomics, Inc., Dr. Saxonov earns $654,990.00 per year.

How do I contact Serge Saxonov?

The corporate mailing address for Dr. Saxonov and other 10x Genomics executives is 6230 STONERIDGE MALL ROAD, PLEASANTON CA, 94588. 10x Genomics can also be reached via email at [email protected]

Has Serge Saxonov been buying or selling shares of 10x Genomics?

During the past quarter, Serge Saxonov has sold $4,685,799.00 in shares of 10x Genomics stock. Most recently, Serge Saxonov sold 772 shares of the business's stock in a transaction on Monday, November 22nd. The shares were sold at an average price of $148.38, for a transaction totalling $114,549.36.

Who are 10x Genomics' active insiders?

10x Genomics' insider roster includes Bradford Crutchfield (Insider), Benjamin Hindson (Insider), Sridhar Kosaraju (Director), Justin McAnear (CFO), Serge Saxonov (CEO), and John Stuelpnagel (Director).

Are insiders buying or selling shares of 10x Genomics?

During the last year, insiders at the sold shares 67 times. They sold a total of 762,236 shares worth more than $128,950,934.97. The most recent insider tranaction occured on November, 22nd when CFO Justin J Mcanear sold 281 shares worth more than $41,694.78. Insiders at 10x Genomics own 11.6 % of the company.

Information on this page was last updated on 11/22/2021.

Serge Saxonov Insider Trading History at 10x Genomics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/22/2021Sell772$148.38$114,549.36View SEC Filing Icon  
11/2/2021Sell15,000$161.25$2,418,750.00View SEC Filing Icon  
10/5/2021Sell15,000$143.50$2,152,500.00View SEC Filing Icon  
9/7/2021Sell15,000$188.42$2,826,300.00View SEC Filing Icon  
8/23/2021Sell742$161.85$120,092.70View SEC Filing Icon  
7/6/2021Sell15,000$193.08$2,896,200.00View SEC Filing Icon  
6/8/2021Sell15,000$186.37$2,795,550.00904,068View SEC Filing Icon  
5/24/2021Sell771$162.66$125,410.86View SEC Filing Icon  
5/4/2021Sell15,000$184.08$2,761,200.00885,676View SEC Filing Icon  
4/6/2021Sell15,000$195.81$2,937,150.00885,676View SEC Filing Icon  
2/1/2021Sell10,000$176.00$1,760,000.00889,576View SEC Filing Icon  
1/4/2021Sell10,000$139.93$1,399,300.00890,468View SEC Filing Icon  
12/1/2020Sell10,000$151.40$1,514,000.00973,431View SEC Filing Icon  
11/2/2020Sell7,076$136.35$964,812.60973,431View SEC Filing Icon  
9/1/2020Sell10,000$113.97$1,139,700.00955,821View SEC Filing Icon  
8/3/2020Sell10,000$99.33$993,300.00963,181View SEC Filing Icon  
7/1/2020Sell10,000$87.58$875,800.00963,181View SEC Filing Icon  
6/1/2020Sell10,000$79.82$798,200.00963,181View SEC Filing Icon  
5/1/2020Sell10,000$77.39$773,900.00955,514View SEC Filing Icon  
4/1/2020Sell10,000$58.07$580,700.00960,514View SEC Filing Icon  
3/6/2020Sell10,000$65.14$651,400.00946,347View SEC Filing Icon  
See Full Table

Serge Saxonov Buying and Selling Activity at 10x Genomics

This chart shows Serge Saxonov's buying and selling at 10x Genomics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

10x Genomics Company Overview

10x Genomics logo
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Read More

Today's Range

Now: $145.85
Low: $140.38
High: $149.09

50 Day Range

MA: $157.72
Low: $142.29
High: $182.59

2 Week Range

Now: $145.85
Low: $128.15
High: $208.99

Volume

34,616 shs

Average Volume

720,963 shs

Market Capitalization

$16.29 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.39
Could This Seattle Pot Stock SOAR as Legal Weed Market Expands?
Fifteen states plus the District of Columbia now permit the recreational use of cannabis and Congress is on track to decriminalize marijuana possession on the federal level. As a result, the North American cannabis market is expected to TRIPLE in size from $30 billion to $100 billion by the year 2027 – and one Seattle manufacturer is poised to cash in!
Details in Brand-New Special Report!